Skip to main content

Rocket Pharmaceuticals, Inc. (RCKT)

NASDAQ: RCKT · IEX Real-Time Price · USD
25.39 0.39 (1.56%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap1.64B
Revenue (ttm)n/a
Net Income (ttm)-185.74M
Shares Out64.44M
EPS (ttm)-2.72
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume219,874
Open24.86
Previous Close25.00
Day's Range23.66 - 25.62
52-Week Range21.38 - 67.48
Beta1.55
AnalystsStrong Buy
Price Target69.78 (+174.8%)
Earnings DateNov 3, 2021

About RCKT

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood ...

IndustryBiotechnology
CEODavid Southwell
Employees91
Stock ExchangeNASDAQ
Ticker SymbolRCKT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for RCKT stock is "Strong Buy." The 12-month stock price forecast is 69.78, which is an increase of 174.83% from the latest price.

Price Target
$69.78
(174.83% upside)
Analyst Consensus: Strong Buy

News

Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

23 hours ago - Business Wire

Rocket Pharmaceuticals to Host In-Person Investor and Analyst Event and Webcast on Tuesday, Dec. 14 at 7:30 a.m. ET t...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

1 day ago - Business Wire

Rocket Pharmaceuticals Announces Participation in Evercore ISI 4th Annual HEALTHCONx Virtual Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

2 weeks ago - Business Wire

Rocket Pharma To Test Lower Dose Of Gene Therapy In Genetic Disorder Trial

Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced updated data from the Phase 1 trial evaluating a single intravenous infusion of RP-A501, an investigational gene therapy, for Danon Disease.  Dano...

3 weeks ago - Benzinga

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

3 weeks ago - Business Wire

Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

3 weeks ago - Business Wire

Rocket Pharmaceuticals Announces Participation in Stifel 2021 Virtual Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

4 weeks ago - Business Wire

Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessio...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

1 month ago - Business Wire

Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Soci...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

1 month ago - Business Wire

Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

1 month ago - Business Wire

Rocket Pharma Posts Interim Data From Immunodeficiency Disorder Gene Therapy Trial

Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced interim data updates from seven patients from the RP-L201 Phase 1/2 trial for Leukocyte Adhesion Deficiency-I (LAD-I). Data were shared at the Ann...

1 month ago - Benzinga

Rocket Pharmaceuticals Announces Positive Clinical Data from RP-L201 Trial for the Treatment of LAD-I at the 28th Ann...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

1 month ago - Business Wire

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 28th Annual Congress of ...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

1 month ago - Business Wire

Rocket Pharmaceuticals to Present at the 2021 Cell & Gene Meeting on the Mesa

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

2 months ago - Business Wire

Rocket Pharmaceuticals to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

2 months ago - Business Wire

Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of Ame...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

2 months ago - Business Wire

Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual S...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

2 months ago - Business Wire

Rocket Pharmaceuticals Appoints Isabel Carmona, J.D., as Chief Human Resources Officer

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

3 months ago - Business Wire

Rocket Pharmaceuticals Announces $26.4 Million Private Placement

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

3 months ago - Business Wire

FDA Lifts Clinical Hold On Rocket Pharma's X-Linked Inherited Disorder Trial

The FDA has lifted the clinical hold on Rocket Pharmaceuticals Inc's (NASDAQ:RCKT) Phase 1 trial of RP-A501 (gene therapy) for Danon Disease, allowing patient enrollment to resume.  The hold was removed...

3 months ago - Benzinga

Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

3 months ago - Business Wire

Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

3 months ago - Business Wire

Rocket Pharmaceuticals to Host Conference Call on Aug. 9 at 4:30 p.m. ET to Discuss Second Quarter Results and Recent...

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders,...

4 months ago - Business Wire

The Pros' Picks: The 11 Best Nasdaq Stocks You Can Buy

A sharp pivot away from growth has given Wall Street a much different perspective on what constitutes today's best Nasdaq stocks. Take a look.

6 months ago - Kiplinger

Rocket Pharmaceuticals Announces Positive Data From RP-L102, RP-L201 Gene Therapy Programs

Rocket Pharmaceuticals Inc (NASDAQ: RCKT) has announced positive data from its Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), and Pyruvate Kinase Deficiency (PKD) gene therapy programs. D...

6 months ago - Benzinga